This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on July 28, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Clinical Laboratory Testing and Specialized Biochemical AnalysisServices for the NHGRI Undiagnosed Diseases Program (UDP) through Baylor Genetics Laboratory

Closed

75N98026Q00900Federal

Submission Closed08/07/2026, 01:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 621511

New

Federal

Q301--Specialized Medical Laboratory Testing Services, VA Palo Alto Health Care System

Solicitation # 36C26126Q1110

Solicitation 36C26126Q1110 is a HUBZone small business set-aside for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide specialized medical laboratory testing services for the VA Palo Alto Health Care System. The contract covers reference laboratory testing that cannot be performed internally by the VA or other contracted laboratories within VISN 21. The period of performance is from November 1, 2026, to October 31, 2027, with a guaranteed minimum award of 2,500 dollars and a maximum aggregate value of 349,999.99 dollars. The scope includes providing all necessary personnel, equipment, and materials to perform tests such as Encephalopathy and Amyloid Protein ID at the contractor's facility, with electronic results generally reported within 7 to 10 business days. Award will be based on the best value to the government, evaluating technical methodology, certifications from CLIA, CAP, or TJC, past performance as a prime contractor within the last five years, and total price. Contractors must comply with strict HIPAA and Privacy Law regulations, VA cybersecurity directives, and OSHA standards. Proposals must be submitted in three separate PDF volumes—Technical, Experience, and Price/Administrative—via email to the designated point of contact by October 7, 2026, at 10:00 AM PDT. Payments will be processed monthly via Electronic Funds Transfer.

261-NETWORK Contract Office 21 (36C261)

POSTED

DEADLINE

Confirmatory Drug Testing Services (GC/MS)This subcontract involves providing high-complexity confirmatory drug testing services for prime contractors working on projects for the Department of Judiciary in the State of Hawaii. The selected provider must utilize Gas Chromatography/Mass Spectrometry (GC/MS) to analyze samples that have triggered positive initial screens, ensuring that all certified confirmatory test reports are delivered within 72 hours of sample submission. To be eligible, the laboratory must be licensed and accredited within the State of Hawaii and fully equipped with the necessary GC/MS instrumentation. This opportunity falls under NAICS code 621511, with a response deadline set for November 23, 2026.

Department of Judiciary

POSTED

DEADLINE

Initial Drug Screening Services (EMIT/Equivalent)This subcontract involves providing initial drug screening services for prime contractors working on projects for the Department of Judiciary in the State of Hawaii. The selected provider must utilize the EMIT system or an approved equivalent to execute Screening Panels I and II, which cover substances including amphetamines, cocaine, cannabinoids, opiates, alcohol, and fentanyl. All initial screening test results must be delivered within 72 hours of sample submission. To qualify, the provider must operate a laboratory equipped for rapid screening that maintains appropriate accreditation. This opportunity falls under NAICS code 621511 and has a response deadline of November 23, 2026.

Department of Judiciary

POSTED

DEADLINE

Urine Specimen Collection ServicesThis subcontract for Urine Specimen Collection Services supports prime contractors on Department of Judiciary projects throughout the State of Hawaii. The selected subcontractor is responsible for the physical collection and secure delivery of urine specimens, operating seven days a week at designated facilities. To ensure the integrity of the process, the provider must adhere to strict, Judiciary-approved written procedures designed to prevent tampering. Eligible providers must maintain a physical collection facility located within the O‘ahu, Maui, Hawai‘i, or Kaua‘i circuits. This opportunity falls under NAICS code 621511, with a response deadline set for November 23, 2026.

Department of Judiciary

POSTED

DEADLINE

Statewide Sample Collection, Drug Screen & Confirmatory Testing

Solicitation # J28030

The Department of Judiciary for the State of Hawaii is soliciting bids under solicitation J28030 for statewide sample collection, initial drug screening, and confirmation testing. The contractor is responsible for collecting urine specimens from individuals referred by the First, Second, Third, and Fifth Circuit courts at their own or an approved subcontractor's facilities. Initial screenings must utilize the EMIT system or an approved equivalent, while confirmation testing must be performed using gas chromatography/mass spectrometry by a company licensed and accredited in Hawaii. The contractor must provide these services seven days a week and submit written procedures to the Officer-in-Charge to ensure samples are not tampered with during collection. The contract is for an initial twenty-four month term from July 1, 2027, through June 30, 2029, with the possibility of two additional twelve-month extensions. Award will be granted to the lowest responsive and responsible bidder, with preferences considered for Hawaii-based products and other statutory categories. Payment is based on the actual number of samples collected per month at the unit bid cost, with invoices submitted separately for each circuit. The contractor must maintain compliance with various Hawaii state laws, including tax clearances, unemployment insurance, and prepaid health care requirements.

Department of Judiciary

POSTED

DEADLINE

Clinical STI Screening and Treatment ServicesThe Clinical STI Screening and Treatment Services subcontract involves providing clinical screening, diagnosis, and medical management of sexually transmitted infections for prime contractors working on East Riding of Yorkshire Council sexual health projects. The scope of work specifically emphasizes Chlamydia screening for females aged 15 to 24 and the early detection of HIV to minimize late-stage presentations. These services are delivered using clinical diagnostic tools and medical examination facilities to ensure patients are accurately diagnosed and treated. The contract is aligned with the Public Health Outcomes Framework indicators, with a primary focus on delivering treated patients and reporting detection rates. Interested parties must respond by November 23, 2026, for this initiative managed by the East Riding of Yorkshire Council under NAICS code 621511.

East Riding of Yorkshire Council

POSTED

DEADLINE

RRC Drug and Alcohol Testing Laboratory ServicesThis subcontract for Residential Reentry Center projects under the Department of Justice involves providing specialized drug and alcohol testing laboratory services for prime contractors. The selected provider will be responsible for the collection and analysis of urine samples to detect narcotics and alcohol, ensuring the delivery of accurate test results and comprehensive reporting. The service provider must maintain strict adherence to regulatory standards, specifically 42 CFR Part 493 (CLIA), P.S. 6060, and P.S. 6590. Performance for this contract is centered in Springfield, falling under NAICS code 621511. Responses are due by November 12, 2026.

Residential Reentry - Co

POSTED

DEADLINE

Substance Abuse Testing and SurveillanceThis subcontract, titled Substance Abuse Testing and Surveillance, is issued by the Department of Justice for Residential Reentry projects. The selected provider will perform random drug and alcohol testing for prime contractors, utilizing urine surveillance, narcotic identification, and breathalyzer equipment. All activities, including testing intervals at facilities and during home visits, must be conducted in strict accordance with BOP P.S. 6060 and P.S. 6590 guidelines to ensure the delivery of verified results and compliance reports. The opportunity is categorized under NAICS code 621511 and was posted on October 28, 2026. Interested parties must submit their responses by the deadline of November 27, 2026.

Residential Reentry - Co

POSTED

DEADLINE

In-Vitro Diagnostics, Point of Care Testing & Pathology Services Project_1717

Solicitation # Project_1717

Supply Chain Coordination Limited, acting for NHS Supply Chain, is establishing an open national framework agreement for the provision of In-Vitro Diagnostic Devices, Point of Care Testing Products, and Related Pathology Services. The scope of the procurement is extensive, covering pathology managed services, reagent rental agreements, pathology software, and core laboratory equipment and consumables across multiple disciplines, including biochemistry, microbiology, immunology, cellular pathology, virology, haematology, genomics, molecular testing, and reproductive sciences. Additionally, the framework includes point of care testing and specimen collection and storage. The procurement is organized into three distinct lots: Pathology Managed Services, Pathology Software Solutions, and Diagnostics Testing Solutions. The estimated total value for the initial period is 703,101,796 GBP excluding VAT, with a potential total value of approximately 2,545,824,000 GBP excluding VAT over the full eight-year framework duration. The estimated contract period runs from October 18, 2027, to October 17, 2029, with an overall framework end date of October 17, 2035. Proposals must be submitted electronically by December 16, 2026. Evaluation for Lots 1 and 2 is weighted at 80 percent for non-financial quality, 10 percent for social value, and 10 percent for price. Lot 3 is evaluated based on 60 percent non-financial quality, 30 percent cost, and 10 percent social value.

Supply Chain Coordination Limited

POSTED

DEADLINE

Pathology ServicesThis subcontract for Pathology Services involves providing diagnostic pathology support for prime contractors working on projects for the Kingston University Higher Education Corporation. The scope of work includes the collection of biological samples and the execution of laboratory analysis utilizing specialized diagnostic equipment and pathology software to deliver comprehensive test results and diagnostic reports. To ensure quality and compliance, the provider must hold recognized laboratory accreditation, such as ISO 15189 or equivalent UK standards. Interested parties must submit their responses by the deadline of November 27, 2026, as specified in the solicitation posted on October 28, 2026.

Kingston University Higher Education Corporation

POSTED

DEADLINE

REBID - IN HOUSE DRUG TESTING SERVICES FOR THE PORT AUTHORITY OF NEW YORK AND NEW JERSEY – FOUR (4) YEAR REQUIREMENTS CONTRACT

Solicitation # 2140325

The Port Authority of New York and New Jersey has issued solicitation number 6000003540 for a four year requirements contract to provide in house drug testing services. This procurement falls under NAICS code 621511 and NIGP codes 94874 for professional medical services and 19300 for clinical laboratory reagents and tests. The contract is designed to ensure the availability of drug monitoring and diagnostic testing services over a multi year period. Interested bidders must submit their proposals electronically via the Euna portal by the deadline of November 10, 2026. The Port Authority has ceased public bid openings, making electronic submission the only accepted method. In accordance with Title VI of the Civil Rights Act of 1964, the agency ensures full and fair opportunity for all businesses regardless of race, color, national origin, age, or disability. Procurement inquiries and submissions are managed by the Procurement Operations office located at 150 Greenwich Street, 21st Floor, New York, New York 10007.

The Port Authority of New York and New Jersey

POSTED

DEADLINE

REBID - FEDERAL DRUG TESTING SERVICES FOR THE PORT AUTHORITY OF NEW YORK AND NEW JERSEY – FOUR (4) YEAR REQUIREMENTS CONTRACT

Solicitation # 2140324

The Port Authority of New York and New Jersey is soliciting bids for solicitation number 6000003539, a four year requirements contract for federal drug testing services. This rebid covers professional medical services and clinical laboratory reagents and tests, specifically falling under NIGP codes 94874 and 19300. The contract will be performed state wide in New York. Bids must be submitted electronically via the Euna portal by November 10, 2026, at 11:00 AM, as the Port Authority has temporarily ceased public bid openings. All procurement activities are conducted in accordance with Title VI of the Civil Rights Act of 1964 to ensure full and fair opportunity without discrimination. For technical assistance or inquiries, the Procurement Operations Bid/RFP Custodian can be reached at [email hidden] or [phone hidden].

The Port Authority of New York and New Jersey

POSTED

2 days ago

DEADLINE

in 11 days

AI Contract Overview

The contract entails the provision of CLIA-certified clinical laboratory testing and specialized biochemical analysis services for the National Human Genome Research Institute’s Undiagnosed Diseases Program, under NIH protocol 15-HG-0130, through Baylor Genetics Laboratory. The work supports the evaluation of patients with complex, rare, and previously undiagnosed multisystem disorders, focusing on genetic, metabolic, and mitochondrial conditions. Services include advanced testing such as mitochondrial DNA copy number quantification, assessment of mitochondrial deletions, metabolomic profiling, biochemical pathway analysis, and testing of tissues including muscle, liver, fibroblasts, blood, and urine, along with follow-up family studies when authorized. All testing must adhere to federal and state regulations, using validated methodologies and maintained quality assurance systems to ensure accuracy and compliance. The contractor is required to deliver comprehensive laboratory reports with clinical interpretations and limitations within established turnaround times, using secure, privacy-compliant transmission methods. Immediate notification of critical or clinically significant findings is mandatory to support urgent patient care. Technical consultation services are essential, including guidance on test selection, specimen handling, result interpretation, and recommendations for additional testing. The contractor must also actively participate in scientific and clinical discussions as requested by NIH. The solicitation, numbered 75N98026Q00900, is issued by the National Institutes of Health within the Department of Health and Human Services, with responses due by August 7, 2026, and performance primarily based in Bethesda, Maryland.

General Info

CLIA-certified genomic and metabolic testing for undiagnosed diseases under NIH protocol, with rapid reporting and clinical consultation.

Agency

Department Of Health And Human Services → National Institutes Of Health Olao

NAICS

621511 - Medical Laboratories

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

Clinical Laboratory Testing and Specialized Biochemical Analysis Services for NHGRI UDP

requirements

High

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJul 28

Presolicitation

Response DeadlineAug 7

Deadline has passed

Submission Closed

08/07/2026, 01:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Office AddressBETHESDA, MD, 20892, USA

Contacts

John Burton

contact@example.gov

Full Description

Requirements:

Title Clinical Laboratory Testing and Specialized Biochemical Analysis Services for the NHGRI Undiagnosed Diseases Program (UDP) through Baylor Genetics Laboratory

1. Background The National Human Genome Research Institute (NHGRI) Undiagnosed Diseases Program (UDP) evaluates patients with complex, chronic, and previously undiagnosed medical conditions. Patients enrolled under NHGRI clinical protocol 15-HG-0130 typically have undergone extensive diagnostic evaluations prior to referral to the National Institutes of Health (NIH) Clinical Center and often present with multisystem disorders requiring advanced diagnostic testing. The UDP seeks to identify underlying disease etiologies, establish accurate diagnoses, and advance scientific understanding of rare and novel genetic conditions. Specialized laboratory testing is required to support diagnostic evaluations and ongoing research efforts associated with rare genetic disorders, mitochondrial diseases, inborn errors of metabolism, and other complex hereditary conditions. The Contractor shall provide Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory testing, interpretation, consultation, and reporting services to support the diagnostic and research objectives of the NHGRI UDP.

2. Objective The objective of this requirement is to obtain specialized clinical laboratory testing and expert interpretation services for UDP patients undergoing evaluation under NIH protocol 15-HG-0130. Services shall support the identification, characterization, and confirmation of rare genetic, metabolic, mitochondrial, and other complex disorders through advanced biochemical, molecular, and metabolomic testing methodologies.

3. Scope of Work The Contractor shall perform CLIA-certified laboratory testing and provide associated interpretive services for biological specimens submitted by the Government. Testing may include, but is not limited to: • Mitochondrial disease evaluations; • Quantitative PCR analysis for mitochondrial DNA copy number; • Assessment of mitochondrial DNA deletions; • Metabolomic analyses; • Biochemical pathway assessments; • Inborn errors of metabolism testing; • Muscle, liver, fibroblast, blood, urine, and other tissue-based analyses; and • Follow-up family studies, when authorized by the Government. The Contractor shall provide laboratory consultation and technical expertise as needed to support interpretation of findings and clinical decision-making. 4. Contractor Requirements The Contractor shall:

4.1 Laboratory Testing a. Perform CLIA-certified laboratory testing on submitted specimens in accordance with applicable federal, state, and accreditation requirements. b. Maintain all certifications, licenses, and quality assurance programs required to perform testing services. c. Conduct testing using validated methodologies and established laboratory procedures.

4.2 Reporting a. Provide written laboratory reports containing test results, interpretations, and any relevant limitations of testing. b. Issue reports within the established turnaround time (TAT) applicable to each test methodology. c. Notify the Government immediately of any critical or clinically significant findings requiring urgent medical attention. d. Provide reports through secure transmission methods compliant with applicable privacy and security regulations.

4.3 Consultation Services a. Provide technical consultation regarding test selection, specimen requirements, interpretation of findings, and follow-up testing recommendations. b. Participate in scientific and clinical discussions related to testing results when requested by the Government.